NCCN临床实践指南:儿童软组织肉瘤(2026.V1)
指南制定者:美国国家综合癌症网络
出处:NCCN官网
发布时间:2026-02-17
1.指南来源(Guide Source):
NCCN临床实践指南:软组织肉瘤 V2.2026.发布已获NCCN肿瘤学临床实践指南(NCCN指南®)许可。©2026美国国家综合癌症网络公司.保留所有权利。未经NCCN明确的书面许可,不得出于任何目的以任何形式复制NCCN指南®和文中的插图。要查看NCCN指南的最新完整版本,请访问NCCN.org。NCCN指南是一项持续进行的工作,可能会随着新的重要数据的出现而不断完善。
2.免责声明(Disclaimers):
NCCN对其内容、使用或应用不做任何形式的担保,并否认以任何方式对其应用或使用承担任何责任。
在下载本篇指南前,请先您详细阅读并同意以下协议:
NCCN内容不得用于商业目的,以及NCCN作为NCCN内容的许可方,不作任何陈述或保证,并明确否认NCCN指南适用于任何特定患者的护理或治疗,任何医院、寻求使用《NCCN指南》治疗患者的临床医生或其他医疗服务提供者(“提供者”)应根据特定患者护理或治疗的具体临床情况做出独立的医疗判断,NCCN不建议、推荐或认可任何提供者(无论是否与被许可方相关)进行任何有偿或无偿的医疗治疗、咨询或服务,也不应因被许可方建议、推荐或认可任何此类提供者的作为或不作为而直接或间接承担责任。详见《NCCN最终用户许可协议》
3.专家名单(Staff):
Stephen Skapek, MD/Chair € ‡
Duke Cancer Center/Duke Children's Hospital & Health Center
Douglas Hawkins, MD/Vice Chair €
Fred Hutchinson Cancer Center/Seattle Children's Hospital
Alyaa Al-Ibraheemi, MD ≠
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Wendy Allen-Rhoades, MD, PhD €
Mayo Clinic Comprehensive Cancer Center
Raffi Avedian, MD τ ¶
Stanford Cancer Institute/Lucile Packard Children's Hospital
Jill Beck, MD €
Seattle Children's Hospital/Fred & Pamela Buffett Cancer Center
Scott Borinstein, MD, PhD €
Monroe Carell Jr. Children's Hospital at Vanderbilt/Vanderbilt-Ingram Cancer Center
Barrett Cromeens, DO, PhD ¶
Indiana University Melvin and Bren Simon Comprehensive Cancer Center/Riley Children's Health
Douglas Fair, MD, MS €
Huntsman Cancer Institute at the University of Utah Primary Children's Hospital
Ajay Gupta, MD € †
Roswell Park Comprehensive Cancer Center/ Roswell Park Oishei Children's Cancer and Blood Disorders Program
Jonathan Kaufman, MD † ¥
Emory Winship Cancer Institute
Margaret Kozak, MD §
UT Southwestern Simmons Comprehensive Cancer Center/Children's Medical Center Dallas
Theodore Laetsch, MD €
Abramson Cancer Center at the University of Pennsylvania/Children's Hospital of Philadelphia
Nicole Larrier, MD, MSc §
Duke Cancer Institute/Duke Children's Hospial & Health Center
Sara Mansfield, MD, MS ¶
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute/Nationwide Children's Hospital
Jonathan Metts, MD € †
Moffitt Cancer Center
Sarah Milgrom, MD §
University of Colorado Cancer Center/Children's Hospital Colorado
Lorenzo Nardo, MD, PhD ф ɸ
UC Davis Comprehensive Cancer Center
Alberto Pappo, MD €
St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
Christine Pratilas, MD €
Johns Hopkins Kimmel Cancer Center/Johns Hopkins Children's Center
Raja Rabah, MD ≠
University of Michigan Rogel Cancer Center/ C.S. Mott Children's Hospital
Jennifer Reichek, MD, MSW € £
Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Ann & Robert H. Lurie Children's Hospital of Chicago
Emily Slotkin, MD €
Memorial Sloan Kettering Cancer Center
Jonathan Swanson, MD, MBA € ф
University of Wisconsin Carbone Cancer Center/American Family Children's Hospital
Juan Vasquez, MD €
Yale Cancer Center/Smilow Cancer Hospital/ Yale New Haven Children's Hospital Lauren Wessel, MD τ ¶
UCLA Jonsson Comprehensive Cancer Center/ UCLA Mattel Children's Hospital
Kimberly Whelan, MD, MSPH € ‡
O'Neal Comprehensive Cancer Center at UAB/ Children's of Alabama Janet Yoon, MD € †
City of Hope National Medical Center
NCCN Cindy Hochstetler, PhD Beth McCullough, RN, BS Katie Stehman, PA-C, MMS
4.临床试验(Clinical Trials):
NCCN认为任何癌症患者都可以在临床试验中得到最佳治疗,因此特别鼓励患者参与临床试验。 寻找NCCN成员组:https://www.nccn.org/home/member-institutions
5.NCCN对证据和共识分类( NCCN Categories of Evidence and Consensus):
推荐均为2A类,除非另有说明,请参见下表:
|
|
NCCN 对证据和共识的分类 |
|
1类 |
基于高水平证据,NCCN一致认为此项治疗合理 |
|
2A类 |
基于低水平证据,NCCN一致认为此项治疗合理 |
|
2B类 |
基于低水平证据,NCCN基本认为此项治疗合理 |
|
3类 |
基于任何水平证据,NCCN对此项治疗是否合理存在重大分歧 |
6.NCCN首选分类( NCCN Categories of Preference):
所有建议均视为合理,请参见下表:
|
|
NCCN 优先使用分类 |
|
首选干预方法 |
若合适,可负担,则基于疗效、安全性和证据更优的干预方法 |
|
推荐的其他干预方法 |
其他繁育方法可能疗效较低,毒性更多,或一句的数据不太成熟;或者具有相似疗效,但费用明显较高 |
|
某些情况下有用 |
其他干预方法可能会用于选定的患者人群(根据推荐类型定义) |
|
|
|
1.指南来源(Guide Source):
NCCN临床实践指南:软组织肉瘤 V2.2026.发布已获NCCN肿瘤学临床实践指南(NCCN指南®)许可。©2026美国国家综合癌症网络公司.保留所有权利。未经NCCN明确的书面许可,不得出于任何目的以任何形式复制NCCN指南®和文中的插图。要查看NCCN指南的最新完整版本,请访问NCCN.org。NCCN指南是一项持续进行的工作,可能会随着新的重要数据的出现而不断完善。
2.免责声明(Disclaimers):
NCCN对其内容、使用或应用不做任何形式的担保,并否认以任何方式对其应用或使用承担任何责任。
在下载本篇指南前,请先您详细阅读并同意以下协议:
NCCN内容不得用于商业目的,以及NCCN作为NCCN内容的许可方,不作任何陈述或保证,并明确否认NCCN指南适用于任何特定患者的护理或治疗,任何医院、寻求使用《NCCN指南》治疗患者的临床医生或其他医疗服务提供者(“提供者”)应根据特定患者护理或治疗的具体临床情况做出独立的医疗判断,NCCN不建议、推荐或认可任何提供者(无论是否与被许可方相关)进行任何有偿或无偿的医疗治疗、咨询或服务,也不应因被许可方建议、推荐或认可任何此类提供者的作为或不作为而直接或间接承担责任。详见《NCCN最终用户许可协议》
3.专家名单(Staff):
Stephen Skapek, MD/Chair € ‡
Duke Cancer Center/Duke Children's Hospital & Health Center
Douglas Hawkins, MD/Vice Chair €
Fred Hutchinson Cancer Center/Seattle Children's Hospital
Alyaa Al-Ibraheemi, MD ≠
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Wendy Allen-Rhoades, MD, PhD €
Mayo Clinic Comprehensive Cancer Center
Raffi Avedian, MD τ ¶
Stanford Cancer Institute/Lucile Packard Children's Hospital
Jill Beck, MD €
Seattle Children's Hospital/Fred & Pamela Buffett Cancer Center
Scott Borinstein, MD, PhD €
Monroe Carell Jr. Children's Hospital at Vanderbilt/Vanderbilt-Ingram Cancer Center
Barrett Cromeens, DO, PhD ¶
Indiana University Melvin and Bren Simon Comprehensive Cancer Center/Riley Children's Health
Douglas Fair, MD, MS €
Huntsman Cancer Institute at the University of Utah Primary Children's Hospital
Ajay Gupta, MD € †
Roswell Park Comprehensive Cancer Center/ Roswell Park Oishei Children's Cancer and Blood Disorders Program
Jonathan Kaufman, MD † ¥
Emory Winship Cancer Institute
Margaret Kozak, MD §
UT Southwestern Simmons Comprehensive Cancer Center/Children's Medical Center Dallas
Theodore Laetsch, MD €
Abramson Cancer Center at the University of Pennsylvania/Children's Hospital of Philadelphia
Nicole Larrier, MD, MSc §
Duke Cancer Institute/Duke Children's Hospial & Health Center
Sara Mansfield, MD, MS ¶
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute/Nationwide Children's Hospital
Jonathan Metts, MD € †
Moffitt Cancer Center
Sarah Milgrom, MD §
University of Colorado Cancer Center/Children's Hospital Colorado
Lorenzo Nardo, MD, PhD ф ɸ
UC Davis Comprehensive Cancer Center
Alberto Pappo, MD €
St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
Christine Pratilas, MD €
Johns Hopkins Kimmel Cancer Center/Johns Hopkins Children's Center
Raja Rabah, MD ≠
University of Michigan Rogel Cancer Center/ C.S. Mott Children's Hospital
Jennifer Reichek, MD, MSW € £
Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Ann & Robert H. Lurie Children's Hospital of Chicago
Emily Slotkin, MD €
Memorial Sloan Kettering Cancer Center
Jonathan Swanson, MD, MBA € ф
University of Wisconsin Carbone Cancer Center/American Family Children's Hospital
Juan Vasquez, MD €
Yale Cancer Center/Smilow Cancer Hospital/ Yale New Haven Children's Hospital Lauren Wessel, MD τ ¶
UCLA Jonsson Comprehensive Cancer Center/ UCLA Mattel Children's Hospital
Kimberly Whelan, MD, MSPH € ‡
O'Neal Comprehensive Cancer Center at UAB/ Children's of Alabama Janet Yoon, MD € †
City of Hope National Medical Center
NCCN Cindy Hochstetler, PhD Beth McCullough, RN, BS Katie Stehman, PA-C, MMS
4.临床试验(Clinical Trials):
NCCN认为任何癌症患者都可以在临床试验中得到最佳治疗,因此特别鼓励患者参与临床试验。 寻找NCCN成员组:https://www.nccn.org/home/member-institutions
5.NCCN对证据和共识分类( NCCN Categories of Evidence and Consensus):
推荐均为2A类,除非另有说明,请参见下表:
|
|
NCCN 对证据和共识的分类 |
|
1类 |
基于高水平证据,NCCN一致认为此项治疗合理 |
|
2A类 |
基于低水平证据,NCCN一致认为此项治疗合理 |
|
2B类 |
基于低水平证据,NCCN基本认为此项治疗合理 |
|
3类 |
基于任何水平证据,NCCN对此项治疗是否合理存在重大分歧 |
6.NCCN首选分类( NCCN Categories of Preference):
所有建议均视为合理,请参见下表:
|
|
NCCN 优先使用分类 |
|
首选干预方法 |
若合适,可负担,则基于疗效、安全性和证据更优的干预方法 |
|
推荐的其他干预方法 |
其他繁育方法可能疗效较低,毒性更多,或一句的数据不太成熟;或者具有相似疗效,但费用明显较高 |
|
某些情况下有用 |
其他干预方法可能会用于选定的患者人群(根据推荐类型定义) |
|
|
|
